Groupe Jazz Pharmaceuticals plc

Action

Marché Fermé - Nasdaq 22:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
260,23 ^USD	+2,26%		+2,83%	+53,08%

25/08	Transcript : Jazz Pharmaceuticals plc - Special Call
25/08	Jazz Pharmaceuticals reçoit l'approbation de la FDA américaine pour Ziihera (zanidatamab-hrii) avec et sans tislelizumab plus chimiothérapie en première ligne de traitement de l'adénocarcinome gastro-œsophagien avancé HER2+	CI

Société	Dirigeant
Jazz Securities DAC Jazz Securities DAC Finance/Rental/LeasingFinance Functions as a financing subsidiary/special purpose entity	-
Jazz Investments II Ltd. Jazz Investments II Ltd. Finance/Rental/LeasingFinance Acts as a financing subsidiary/Special purpose entity	-
Jazz Financing Holdings Ltd. Jazz Financing Holdings Ltd. MiscellaneousMiscellaneous Functions as an investment holding company	-
Jazz Investments Europe Ltd.	-
Jazz Pharmaceuticals Ireland Ltd. Jazz Pharmaceuticals Ireland Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on the identification, development and commercialization of pharmaceutical products	Bruce Cozadd
Jazz Financing I DAC Jazz Financing I DAC Finance/Rental/LeasingFinance Issues Asset-backed/Mortgage-backed/Structured Finance securities	-
Jazz Pharmaceuticals Ireland Holdings Ltd.	-
Jazz Financing Lux SARL Jazz Financing Lux SARL Finance/Rental/LeasingFinance Provides financing services	-